MiNK Therapeutics, Inc. (INKT) shareholders
Close on Nov 17, 2026Market cap $47.38MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Gkcc, LLC | 4,640,000 | 11.79% | 13G (passive) | May 14, 2024 |
| Garo H. Armen | 3,514,320 | 9.68% | 13D (active) | Jan 16, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INKT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 68,660 | 1.35% | $802.64K | +9,296 | 0.00% |
| DnB Asset Management AS | 55,142 | 1.08% | $644.61K | New | 0.00% |
| Longbow Finance SA | 16,667 | 0.33% | $194.84K | – | 0.02% |
| Geode Capital Management, LLC | 15,573 | 0.31% | $182.08K | −1,772 | 0.00% |
| Citadel Advisors LLC | 15,440 | 0.30% | $180.49K | New | 0.00% |
| BlackRock, Inc. | 13,382 | 0.26% | $156.44K | +7,179 | 0.00% |
| Vanguard Fiduciary Trust Co | 8,287 | 0.16% | $96.88K | – | 0.00% |
| UBS Group AG | 4,885 | 0.10% | $57.11K | −10,317 | 0.00% |
| Steward Partners Investment Advisory, LLC | 2,000 | 0.04% | $23.38K | – | 0.00% |
| US Bancorp \de\ | 1,995 | 0.04% | $23.32K | New | 0.00% |
| Paladin Partners, LLC | 1,000 | 0.02% | $11.69K | – | 0.01% |
| Federation des caisses Desjardins du Quebec | 500 | 0.01% | $5.85K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 422 | 0.01% | $4.93K | +266 | 0.00% |
| Covestor Ltd | 119 | 0.00% | $1.00K | – | 0.00% |
| Osaic Holdings, Inc. | 117 | 0.00% | $1.37K | +116 | 0.00% |
| Morgan Stanley | 113 | 0.00% | $1.32K | +9 | 0.00% |
| Barclays PLC | 24 | 0.00% | $281 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 18 | 0.00% | $210 | +8 | 0.00% |
| Northwestern Mutual Wealth Management Co | 18 | 0.00% | $210 | – | 0.00% |
| Game Plan Financial Advisors, LLC | 16 | 0.00% | $187 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 0M | 4.0% | 7 / 6 | 3 / 3 | 0M | 0M |
| Q1 2026 | 23 | 0M | 2.5% | 5 / 2 | 4 / 5 | 0M | 0M |
| Q4 2025 | 24 | 0M | 3.0% | 6 / 3 | 7 / 0 | 0M | 0M |
| Q3 2025 | 18 | 0M | 1.8% | 2 / 6 | 2 / 3 | 0M | 0M |
| Q2 2025 | 19 | 0M | 1.2% | 4 / 5 | 5 / 1 | 0M | 0M |
| Q1 2025 | 16 | 0M | 0.9% | 16 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
10 funds held INKT in Q2 2026, 86% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INKT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 53,070 | 1.04% | $620.39K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 15,382 | 0.30% | $179.82K | 0.00% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 6,734 | 0.13% | $78.72K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 6,599 | 0.13% | $80.51K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,902 | 0.04% | $23.20K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 1,883 | 0.04% | $22.97K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 1,389 | 0.03% | $16.95K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 445 | 0.01% | $5.20K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 208 | 0.00% | $2.43K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -200 | -0.00% | -$2.34K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jennifer Buell | Chief Executive Officer, Director | 74,195 | 1.45% | Oct 14, 2026 |
| Melissa Orilall | Principal Financial Officer | 222 | 0.00% | Apr 9, 2026 |
| Austin Charette | Principal Accounting Officer | 40 | 0.00% | Mar 23, 2026 |
| Brian Corvese | Director | 54,770 | 1.07% | Sep 2, 2026 |
| John Bradley Holcomb | Director | 4,691 | 0.09% | Sep 2, 2026 |
| Ulf Wiinberg | Director | 51,759 | 1.01% | Sep 2, 2026 |
| Barbara Ryan | Director | 23,591 | 0.46% | Sep 2, 2026 |
| Peter Behner | Director | 24,404 | 0.48% | Sep 2, 2026 |
| Robert Peter Kadlec | Director | 19,126 | 0.37% | Dec 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Buell Chief Executive Officer, Director | Oct 12, 2026 | Sale | −6,938 | $10.56 | $73.27K | 74,195 |
| Jennifer Buell Chief Executive Officer, Director | Oct 11, 2026 | Option exercise | +23,191 | – | – | 81,133 |
| John Bradley Holcomb Director | Sep 1, 2026 | Award | +1,233 | $10.95 | $13.50K | 4,691 |
| Ulf Wiinberg Director | Sep 1, 2026 | Award | +1,279 | $10.95 | $14.01K | 23,929 |
| Brian Corvese Director | Sep 1, 2026 | Award | +1,633 | $10.95 | $17.88K | 54,770 |
| Peter Behner Director | Sep 1, 2026 | Award | +1,485 | $10.95 | $16.26K | 24,404 |
| Barbara Ryan Director | Sep 1, 2026 | Award | +1,622 | $10.95 | $17.76K | 23,591 |
| Barbara Ryan Director | Jun 4, 2026 | Sale | −500 | $12.68 | $6.34K | 22,969 |
| Barbara Ryan Director | Jun 4, 2026 | Sale | −1,000 | $12.80 | $12.80K | 21,969 |
| Ulf Wiinberg Director | Jun 1, 2026 | Award | +1,131 | $12.38 | $14.00K | 22,650 |
| John Bradley Holcomb Director | Jun 1, 2026 | Award | +1,091 | $12.38 | $13.51K | 3,458 |
| Barbara Ryan Director | Jun 1, 2026 | Award | +1,434 | $12.38 | $17.75K | 23,469 |
| Brian Corvese Director | Jun 1, 2026 | Award | +1,444 | $12.38 | $17.88K | 53,137 |
| Peter Behner Director | Jun 1, 2026 | Award | +1,313 | $12.38 | $16.25K | 22,919 |
| Barbara Ryan Director | Mar 10, 2026 | Sale | −300 | $15.28 | $4.58K | 21,406 |
| Barbara Ryan Director | Mar 10, 2026 | Sale | −500 | $15.57 | $7.79K | 20,906 |
| Barbara Ryan Director | Mar 10, 2026 | Sale | −500 | $15.30 | $7.65K | 20,406 |
| Barbara Ryan Director | Mar 9, 2026 | Sale | −200 | $10.17 | $2.03K | 21,706 |
| Ulf Wiinberg Director | Mar 2, 2026 | Award | +1,285 | $10.90 | $14.01K | 21,519 |
| John Bradley Holcomb Director | Mar 2, 2026 | Award | +1,239 | $10.90 | $13.51K | 2,367 |
| Barbara Ryan Director | Mar 2, 2026 | Award | +1,629 | $10.90 | $17.76K | 22,035 |
| Brian Corvese Director | Mar 2, 2026 | Award | +1,640 | $10.90 | $17.88K | 51,693 |
| Peter Behner Director | Mar 2, 2026 | Award | +1,491 | $10.90 | $16.25K | 21,606 |
| Barbara Ryan Director | Mar 2, 2026 | Sale | −100 | $10.83 | $1.08K | 21,906 |
| Barbara Ryan Director | Feb 27, 2026 | Sale | −400 | $10.86 | $4.34K | 22,006 |
| Jennifer Buell Chief Executive Officer | Jan 2, 2026 | Tax withholding | −10,024 | $11.12 | $111.47K | 57,942 |
| Jennifer Buell Chief Executive Officer | Jan 2, 2026 | Award | +31,474 | $11.12 | $349.99K | 67,966 |
| John Bradley Holcomb Director | Dec 1, 2025 | Award | +1,128 | $11.09 | $12.51K | 1,128 |
| Peter Behner Director | Dec 1, 2025 | Award | +1,466 | $11.09 | $16.26K | 20,115 |
| Robert Peter Kadlec Director | Dec 1, 2025 | Award | +1,218 | $11.09 | $13.51K | 19,126 |
| Ulf Wiinberg Director | Dec 1, 2025 | Award | +1,263 | $11.09 | $14.01K | 20,234 |
| Barbara Ryan Director | Dec 1, 2025 | Award | +1,601 | $11.09 | $17.76K | 22,406 |
| Brian Corvese Director | Dec 1, 2025 | Award | +1,612 | $11.09 | $17.88K | 50,053 |
| Jennifer Buell Chief Executive Officer | Sep 9, 2025 | Tax withholding | −5,351 | $15.36 | $82.19K | 36,492 |
| Jennifer Buell Chief Executive Officer | Sep 9, 2025 | Award | +18,229 | $15.36 | $280.00K | 41,913 |
| Barbara Ryan Director | Sep 2, 2025 | Award | +1,281 | $13.86 | $17.75K | 20,805 |
| Robert Peter Kadlec Director | Sep 2, 2025 | Award | +975 | $13.86 | $13.51K | 17,908 |
| Ulf Wiinberg Director | Sep 2, 2025 | Award | +1,011 | $13.86 | $14.01K | 18,971 |
| Brian Corvese Director | Sep 2, 2025 | Award | +1,290 | $13.86 | $17.88K | 48,441 |
| Peter Behner Director | Sep 2, 2025 | Award | +1,173 | $13.86 | $16.26K | 18,649 |
| Brian Corvese Director | Jun 2, 2025 | Award | +2,494 | $7.17 | $17.88K | 47,151 |
| Ulf Wiinberg Director | Jun 2, 2025 | Award | +1,953 | $7.17 | $14.00K | 17,960 |
| Barbara Ryan Director | Jun 2, 2025 | Award | +2,476 | $7.17 | $17.75K | 19,524 |
| Robert Peter Kadlec Director | Jun 2, 2025 | Award | +1,883 | $7.17 | $13.50K | 4,647 |
| Peter Behner Director | Jun 2, 2025 | Award | +2,267 | $7.17 | $16.25K | 17,476 |
| Brian Corvese Director | Mar 3, 2025 | Award | +2,033 | $8.79 | $17.87K | 44,657 |
| Robert Peter Kadlec Director | Mar 3, 2025 | Award | +1,536 | $8.79 | $13.50K | 2,764 |
| Barbara Ryan Director | Mar 3, 2025 | Award | +2,019 | $8.79 | $17.75K | 17,048 |
| Ulf Wiinberg Director | Mar 3, 2025 | Award | +1,593 | $8.79 | $14.00K | 16,007 |
| Peter Behner Director | Mar 3, 2025 | Award | +1,849 | $8.79 | $16.25K | 15,209 |
| Robert Peter Kadlec Director | Dec 1, 2024 | Award | +12,286 | $0.73 | $8.97K | 12,286 |
| Barbara Ryan Director | Dec 1, 2024 | Award | +24,229 | $0.73 | $17.69K | 150,336 |
| Peter Behner Director | Dec 1, 2024 | Award | +20,987 | $0.73 | $15.32K | 133,634 |
| Ulf Wiinberg Director | Dec 1, 2024 | Award | +20,476 | $0.73 | $14.95K | 144,181 |
| Brian Corvese Director | Dec 1, 2024 | Award | +24,400 | $0.73 | $17.81K | 426,283 |
| Ulf Wiinberg Director | Sep 3, 2024 | Award | +18,295 | $0.82 | $15.00K | 123,705 |
| Barbara Ryan Director | Sep 3, 2024 | Award | +21,649 | $0.82 | $17.75K | 126,107 |
| Peter Behner Director | Sep 3, 2024 | Award | +18,753 | $0.82 | $15.38K | 109,234 |
| Brian Corvese Director | Sep 3, 2024 | Award | +21,802 | $0.82 | $17.88K | 405,296 |
| Peter Behner Director | Jun 3, 2024 | Award | +15,454 | $0.99 | $15.30K | 90,481 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MiNK Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,483 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jennifer Buell Officer, PRESIDENT AND CHIEF EXECUTIVE OFFICER | Oct 13, 2026 | 6,938 | $73.27K | Oct 12, 2026 | RESTRICTED STOCK UNITS VESTING |
| Agenus Inc. Owner | Aug 29, 2025 | 786,750 | $12.57M | Aug 29, 2025 | These shares were acquired in an original issuance from the issuer, which was incorporated as a wholly owned subsidiary of Agenus Inc. |
See a number that looks wrong?